Manufacturer record
Medistream Bioscience: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Medistream Bioscience was declared Not of Standard Quality in October 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: MB-13247, Ramipril Tablets IP (Rexre-2.5) (exp Dec 2027). DTL, Thrissur, Kerala (state lab) found it not of standard quality: Sample does not conform IP standard as it fails the test Dissolution and Assay of Ramipiril. Listed in the October 2025 alert.
Records by type
1 record linked to Medistream Bioscience in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Ramipril Tablets IP (Rexre-2.5) | Batch MB-13247Mfg Jan 2025 · Exp Dec 2027 | Sample does not conform IP standard as it fails the test Dissolution and Assay of RamipirilAssay | DTL, Thrissur, KeralaState lab | Oct 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.